Marshall Wace LLP Makes New Investment in Fate Therapeutics, Inc. (NASDAQ:FATE)
Marshall Wace LLP bought a new position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 512,641 shares of the biopharmaceutical company’s stock, valued at approximately $846,000. Marshall Wace LLP owned approximately 0.45% of Fate […]
Marshall Wace LLP bought a new position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 512,641 shares of the biopharmaceutical company’s stock, valued at approximately $846,000. Marshall Wace LLP owned approximately 0.45% of Fate […]
